Baidu
map

盘点:JACC三月第一期研究一览

2019-03-11 不详 MedSci原创

1.操作时间对血管内血栓切除术预后的影响研究<span style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:宋体; mso-bidi-font-family:'Times New Roman';font-size:10.5000pt;mso-font-kerning:1.0000pt;">DOI: 10.10

1.操作时间对血管内血栓切除术预后的影响研究

DOI: 10.1016/j.jacc.2018.11.052

 

血管内血栓切除术(ET)是目前治疗急性缺血性卒中的标准方法,尽管成功的ET可以明显改善患者预后,但是更长的操作时间(PT)与更低的功能独立率相关。本研究的目的旨在评估操作时间对ET术后患者的预后和并发症的影响。本研究纳入了来自7个美国医疗中心的1359名接受ET治疗的患者,分析结果显示当操作时间超过30min后会降低患者的预后(p < 0.01),术后出血率和并发症发生率随着操作时间呈指数增加。成功再通的累积率和良好的预后在PT超过60min后达到稳定期。在PT30min的患者中,更少的尝试可以预测ET的成功和良好的预后(p < 0.01)。研究结果显示,在接受血管内血栓切除术治疗的患者中,操作时间越长,术后出血和并发症的发生风险越高。

 

2.进行性恶化心衰的临床特征研究

DOI: 10.1016/j.jacc.2018.11.049

 

进行性恶化的心衰伴射血分数降低(HFrEF)患者的流行病学特征尚不完整。本研究的目的旨在评估进行性恶化的HFrEF患者的发病率、临床特征、治疗和预后。本研究纳入分析了11064HFrEF患者,其中1851名(17%)患者在平均1.5年后发展为进行性恶化的HFrEF患者。发展为进行性恶化的HFrEF患者更多的是非洲裔美国人,年龄多在80-90岁之间,并发症的负担更高(p < 0.001)。在进行性恶化HF形成后,42.4%的患者接受的是单一疗法,43.4%的患者接受的是双重疗法,14.1%的患者接受的是三重疗法。总共48%61%98%的患者分别接受了血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、β受体阻滞剂和盐皮质激素受体拮抗剂的目标剂量>50%的治疗。另外,患者2年的死亡率是22.5%56%的患者在发展为进行性恶化HF30天内再住院治疗。研究结果显示,有约六分之一的心衰伴射血分数降低的患者会在诊断18个月内发展为进行性恶化的心衰,这些患者的2年死亡率和再住院风险明显更高。

 

3.极低体重房颤患者的抗凝治疗——DOACs vs 华法林

DOI: 10.1016/j.jacc.2018.11.051

 

目前,对于非瓣膜性房颤AF)和极低体重(50kg)患者,直接口服抗凝药物(DOACs)的有效性和安全性尚不清楚。本研究的目的旨在评估和比较DOACs和华法林对极低体重AF患者的效果。本研究纳入了韩国国家数据库中的接受口服抗凝药物治疗的体重≤60kgAF患者(DOACs n=14013;华法林 n=7576),并用倾向性评分调整两组患者。分析结果显示,与华法林相比,DOACs 与更低的缺血性卒中([HR]0.59195% [CI]0.510-0.686)和主要出血事件相关(HR0.70595%CI 0.601-0.825),而这些均由颅内出血的减少(HR0.55495% CI0.429-0.713)导致。另外,DOACs 可以提高临床净效益(HR0.66095% CI0.606-0.717),这些结果在体重<50kg的患者中是一致的。研究结果显示,对于极低体重AF患者,直接口服抗凝药物的有效性和安全性优于华法林。


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854332, encodeId=7ca1185433253, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 14 09:10:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367041, encodeId=a6ae36e04115, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri May 31 07:29:12 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364210, encodeId=1a293642105c, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Apr 06 10:55:54 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326150, encodeId=111313261508b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Mar 13 07:10:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362470, encodeId=37003624e0d0, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 11 20:49:11 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2019-10-14 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854332, encodeId=7ca1185433253, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 14 09:10:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367041, encodeId=a6ae36e04115, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri May 31 07:29:12 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364210, encodeId=1a293642105c, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Apr 06 10:55:54 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326150, encodeId=111313261508b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Mar 13 07:10:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362470, encodeId=37003624e0d0, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 11 20:49:11 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2019-05-31 一天没事干

    很好的学习机会

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1854332, encodeId=7ca1185433253, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 14 09:10:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367041, encodeId=a6ae36e04115, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri May 31 07:29:12 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364210, encodeId=1a293642105c, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Apr 06 10:55:54 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326150, encodeId=111313261508b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Mar 13 07:10:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362470, encodeId=37003624e0d0, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 11 20:49:11 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2019-04-06 一天没事干

    很好的学习机会

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1854332, encodeId=7ca1185433253, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 14 09:10:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367041, encodeId=a6ae36e04115, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri May 31 07:29:12 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364210, encodeId=1a293642105c, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Apr 06 10:55:54 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326150, encodeId=111313261508b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Mar 13 07:10:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362470, encodeId=37003624e0d0, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 11 20:49:11 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854332, encodeId=7ca1185433253, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 14 09:10:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367041, encodeId=a6ae36e04115, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri May 31 07:29:12 CST 2019, time=2019-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364210, encodeId=1a293642105c, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sat Apr 06 10:55:54 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326150, encodeId=111313261508b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Mar 13 07:10:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362470, encodeId=37003624e0d0, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Mar 11 20:49:11 CST 2019, time=2019-03-11, status=1, ipAttribution=)]
    2019-03-11 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

JAHA:中度主动脉狭窄患者的远期预后研究

中度主动脉狭窄(MAS)尚未被研究的十分清楚。本研究的目的旨在评估MAS患者的临床特征和远期预后。本研究纳入了508例MAS伴保留型左室射血分数的患者(平均年龄 75±11岁)。大多数患者(86.4%)无临床症状或很轻,78.3%的患者有高血压,36.2%的患者有糖尿病,48.3%的患者有血脂异常。经过平均47个月时间的随访,113名(22.2%)患者因严重AS接受了主动脉瓣置换术,入组到手术的平

Eur Heart J:非布索坦预防脑、心血管或肾脏疾病疗效

由此可见,非布索坦可降低尿酸并延缓肾功能障碍的进展。

JAHA:外周动脉疾病患者血压越低,心血管风险越高

在外周动脉疾病患者中,高血压是一个心血管疾病的危险因素,然而这类患者的理想血压尚不清楚。本研究的目的旨在评估外周动脉疾病患者收缩压(SBP)与心血管疾病的相关性。本研究纳入了2773名患者,根据血压分为SBP≤120 mm Hg, n=604; 121–140 mm Hg, n=1065; 和 >140 mm Hg, n=1104。多元回归分析后发现与SBP在121–140 mm Hg的患者

JAHA:周围环境的绿化程度与心脏病风险呈相关性!

多接触大自然可能会降低心脏病的发病风险,本研究的目的旨在评估周围环境的绿化与4种心脏病(急性心梗、缺血性心脏病、心衰和房颤)的相关性。本研究纳入了249405名医保受益人,分析结果发现,在经调整个人社会人口和邻里收入后,环境绿化的增加可降低心脏病的发病风险。与绿化程度最低的三分之一相比,绿化程度最高的三分之一对象的急性心梗风险降低25%(OR:0.75; 95% CI, 0.63–0.90),缺血

JAHA:射血分数改善型心衰的临床特征研究

许多射血分数降低型心衰(HFrEF)患者会经历左室射血分数(LVEF)的提高和改善。对于射血分数改善型心衰(HFiEF)患者的临床特征和预后尚不清楚。KorAHF 临床研究纳入了5625名因急性心衰住院的患者,其中5103名患者基线水平有超声心动图检查,2302名在随访12个月后有超声心动图检查。患者的心衰可以分为固执型HFrEF(随访一年后LVEF ≤40%),HFiEF(基线水平LVEF ≤4

JACC:极低体重房颤患者的抗凝治疗——DOACs vs 华法林

目前,对于非瓣膜性房颤(AF)和极低体重(50kg)患者,直接口服抗凝药物(DOACs)的有效性和安全性尚不清楚。本研究的目的旨在评估和比较DOACs和华法林对极低体重AF患者的效果。本研究纳入了韩国国家数据库中的接受口服抗凝药物治疗的体重≤60kg的AF患者(DOACs n=14013;华法林 n=7576),并用倾向性评分调整两组患者。分析结果显示,与华法林相比,DOACs 与更低的缺血性卒中

Baidu
map
Baidu
map
Baidu
map